The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.
Discovery of a Mutant-Selective Covalent Inhibitor of EGFR that Overcomes T790M-Mediated Resistance in NSCLC
Open accessPublished version of a preprint
Abstract
Patients with non–small cell lung cancer (NSCLC) with activating EGF receptor (EGFR) mutations initially respond to first-generation reversible EGFR tyrosine kinase inhibitors. However, clinical efficacy is limited by acquired resistance, frequently driven by the EGFRT790M mutation. CO-1686 is a novel, irreversible, and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR, including T790M, while exhibiting minimal activity toward the wild-type (WT) receptor. Oral administration of CO-1686 as single agent induces tumor regression in EGFR-mutated NSCLC tumor xenograft and transgenic models. Minimal activity of CO-1686 against the WT EGFR receptor was observed. In NSCLC cells with acquired resistance to CO-1686 in vitro, there was no evidence of additional mutations or amplification of the EGFR gene, but resistant cells exhibited signs of epithelial–mesenchymal transition and demonstrated increased sensitivity to AKT inhibitors. These results suggest that CO-1686 may offer a novel therapeutic option for patients with mutant EGFR NSCLC. Significance: We report the preclinical development of a novel covalent inhibitor, CO-1686, that irreversibly and selectively inhibits mutant EGFR, in particular the T790M drug-resistance mutation, in NSCLC models. CO-1686 is the first drug of its class in clinical development for the treatment of T790M-positive NSCLC, potentially offering potent inhibition of mutant EGFR while avoiding the on-target toxicity observed with inhibition of the WT EGFR. Cancer Discov; 3(12); 1404–15. ©2013 AACR. This article is highlighted in the In This Issue feature, p. 1317
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Rociletinib (XegafriTM, CO-1686) (65), developed by Clovis Oncology, is a specific mutant agent for the treatment of NSCLC, belonging to the third-generation EGFR TKIs.190,191”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [190]
In the citing paper
“Additionally, covalent inhibitors can exhibit high selectivity for proteins with non-conserved residues between variant forms or protein family members [41].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [41]
In the citing paper
“AZD9291 has a distinct chemical structure from the other third-generation TKIs, WZ4002 (34) and CO-1686 (35).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [35]
In the citing paper
“Indeed, pre-clinical reports have suggested that “third generation” agents can induce switching to multiple signaling mechanisms that bypass EGFR dependency such as ERK and AKT pathways (35, 61, 62).”
From AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung Cancer (2014) · cites this paper as [35]
In the citing paper
“Preclinical studies have confirmed that rociletinib has minimal activity against wild-type EGFR.7”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [7]
In the citing paper
“Rociletinib (CO-1686) is an EGFR inhibitor active in preclinical models of EGFR-mutated NSCLC with or without T790M.”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [7]
In the citing paper
“In xenograft models with EGFR-activating mutations alone or combined with T790M resistance mutations, rociletinib resulted in durable tumor shrinkage, 7 which was most marked when plasma concentrations were maintained at more than 200 ng per milliliter across the dosing interval.”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [7]
In the citing paper
“Rociletinib (CO-1686; Clovis Oncology) is a small-molecule, orally available, mutant-selective covalent inhibitor of commonly mutated forms of EGFR, including exon 19 deletions, L858R, and T790M, but not exon 20 insertions.”
From Rociletinib in EGFR-Mutated Non–Small-Cell Lung Cancer (2015) · cites this paper as [7]
In the citing paper
“Indeed, it seems that EGFR monoclonal antibodies 60 and EGFR WT kinase sparing covalent T790M selective TKIs 61 are ineffective in typical EGFR exon 20 insertion mutants.”
From Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer (2013) · cites this paper as [61]
In the citing paper
“Cysteine 797 is the site of covalent binding for all three of these agents (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [15]
In the citing paper
“They are not only more potent on EGFR T790M, but also selectively inhibit mutant over WT EGFR and hence should lead to increased clinical efficacy and less toxicity compared with afatinib (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [15]
In the citing paper
“These include the development of mutant selective EGFR kinase inhibitors, including WZ4002, CO-1686 and AZD9291, which to date have demonstrated encouraging efficacy in both preclinical models and in EGFR mutant NSCLC patients with EGFR T790M mediated drug resistance (14–18).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [15]
In the citing paper
“CO-1686 is structurally more closely related to WZ4002 than to AZD9291 and in all of the models tested CO-1686 is very similar in vitro to WZ4002 (14–16).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [15]
In the citing paper
“Additional pre-clinical studies have also identified activation of MAPK signaling and IGF1R signaling as well as epithelial to mesenchymal (EMT) transition as potential resistance mechanisms to WZ4002 and CO-1686 (15, 19, 20).”
From EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors (2015) · cites this paper as [15]
In the citing paper
“In vitro and in vivo studies demonstrated that Rociletinib irreversibly and selectively inhibits mutant EGFR, including T790M mutation, with minimal activity against wild type EGFR, suggesting that drug tolerability to this agent may be superior to first and second generation EGFR inhibitors”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [85]
In the citing paper
“Both 2G and 3G EGFR‐TKI are irreversible small‐molecule inhibitors that covalently bind to EGFR kinase by targeting the cysteine‐797 residue, located in the ATP binding pocket, and 3G EGFR‐TKI are considered to be more specific for EGFR sensitizing mutations than 2G EGFR‐TKI.12, 13, 14”
In the citing paper
“Osimertinib and rociletinib are 3rd generation EGFR-TKIs, both of which are reported to be effective in lung cancer cells harboring EGFR T790M in preclinical models [30, 32].”
In the citing paper
“A third generation of EGFR inhibitors followed afatinib; these covalent inhibitors selectively target the T790M mutant over wild-type EGFR, and include WZ4002 (Dana–Farber Cancer Institute)43, osimertinib44,45 and rociletinib (Clovis Oncology; CO-1686)46 (Fig. 2c).”
From Advances in covalent drug discovery (2022) · cites this paper as [46]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261 · cited 1×
“Patients with the most common EGFR mutations (L858R mutation in exon 21 and delE746-A750 deletions in exon 19) typically have good responses to therapy with first-generation reversible EGFR tyrosine kinase inhibitors (TKIs), such as erlotinib or gefitinib (3-5).”
Rosell, R., Carcereny, E., Gervais, R., Vergnenegre, A., Massuti, B., Felip, E., Palmero, R., Garcia-Gomez, R., Pallares, C., Sanchez, J. M., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70393-x · Cited by 5,489
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationEGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Pao, W., Miller, V. A., Politi, K. A., Riely, G. J., Somwar, R., Zakowski, M. F., Kris, M. G., & Varmus, H. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020073 · Cited by 3,527 · cited 2×
“second site EGFR point mutation that results in the substitution of threonine with methionine at amino acid position 790 (T790M;(7-10)).”
BackgroundSelf-citationGenotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Bergethon, K., Shaw, A. T., Gettinger, S., Cosper, A. K., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002003 · Cited by 3,499
Epidermal growth factor receptor mutations in lung cancer
Sharma, S. V., Bell, D. W., Settleman, J., & Haber, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2088 · Cited by 3,170
A quantitative analysis of kinase inhibitor selectivity
Karaman, M. W., Herrgard, S., Treiber, D. K., Gallant, P., Atteridge, C. E., Campbell, B. T., Chan, K. W., Ciceri, P., Davis, M. I., Edeen, P. T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1358 · Cited by 2,466
Yu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454
Self-citation
Cited by
Sorted by citations
Items 301–400 of 686
Application of peptide displaying phage as a novel diagnostic probe for human lung adenocarcinoma
Lee, K. J., Lee, J. H., Chung, H. K., Ju, E. J., Song, S. Y., Jeong, S., & Choi, E. K. (2016) · Amino Acids · doi:10.1007/s00726-015-2153-4 · Cited by 31
Self-citationRecent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC
Bansal, P., Osman, D. I., Gan, G. N., Simon, G. R., & Boumber, Y. (2016) · Frontiers in Oncology · doi:10.3389/fonc.2016.00112 · Cited by 31
Re, M. D., Petrini, I., Mazzoni, F., Valleggi, S., Gianfilippo, G., Pozzessere, D., Chella, A., Crucitta, S., Rofi, E., Restante, G., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.10.003 · Cited by 30
Li, Q., Guo, Q., Wang, S., Wan, S., Li, Z., Zhang, J., & Wu, X. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114455 · Cited by 31
Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
Soejima, K., Yasuda, H., & Hirano, T. (2016) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1265446 · Cited by 31
Hao, Y., Wang, X., Zhang, T., Sun, D., Tong, Y., Xu, Y., Chen, H., Tong, L., Zhu, L., Zhao, Z., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00403 · Cited by 29
Yang, G., Jin, Y., Wang, C., Zhang, J., Tang, Z., Peng, J., Liu, K., Li, Y., Zhou, Y., & Ma, X. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00235 · Cited by 29
HDGF and PRKCA upregulation is associated with a poor prognosis in patients with lung adenocarcinoma
Jiang, H., Fu, Q., Song, X., Ge, C., Li, R., Li, Z., Zeng, B., Li, C., Wang, Y., Xue, Y., et al. (2019) · Oncology Letters · doi:10.3892/ol.2019.10812 · Cited by 29
Janpipatkul, K., Trachu, N., Watcharenwong, P., Panvongsa, W., Worakitchanon, W., Metheetrairut, C., Oranratnachai, S., Reungwetwattana, T., & Chairoungdua, A. (2021) · Cancer Biomarkers · doi:10.3233/cbm-203075 · Cited by 29
Nossier, E. S., Alasfoury, R. A., Hagras, M., El‐Manawaty, M. A., Sayed, S. M., Ibrahim, I. M., Elkady, H., Eissa, I. H., & Elzahabi, H. S. A. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2022.133971 · Cited by 29
So, K. S., Kim, C. H., Rho, J. K., Kim, S. Y., Choi, Y. J., Song, J. S., Kim, W. S., Choi, C., Chun, Y. J., & Lee, J. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0114000 · Cited by 29
Hawkinson, J. E., Sinville, R., Mudaliar, D. J., Shetty, J., Ward, T. R., Herr, J. C., & Georg, G. I. (2017) · ChemMedChem · doi:10.1002/cmdc.201700503 · Cited by 29
Assadollahi, V., Rashidieh, B., Alasvand, M., Abdolahi, A., & López, J. A. (2019) · Journal of Cellular Biochemistry · doi:10.1002/jcb.28575 · Cited by 29
Personalized treatment of advanced non-small-cell lung cancer in routine clinical practice
Pirker, R., & Filipits, M. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9612-6 · Cited by 28
Su, K., Tseng, J., Liao, K.-M., Yang, T., Chen, K., Hsu, K.-H., Yang, P., Yu, S., & Chang, G. (2018) · PLoS ONE · doi:10.1371/journal.pone.0207001 · Cited by 29
Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer
Delahaye, C., Figarol, S., Pradines, A., Favre, G., Mazières, J., & Calvayrac, O. (2022) · Cancers · doi:10.3390/cancers14112613 · Cited by 32
Fukuda, T., Umeki, T., Tokushima, K., Gao, X., Yoshida, Y., Ishibashi, F., Oku, Y., Nishiya, N., Uehara, Y., & Iwao, M. (2017) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2017.10.030 · Cited by 28
Fawwaz, M., Mishiro, K., Nishii, R., Sawazaki, I., Shiba, K., Kinuya, S., & Ogawa, K. (2020) · Molecules · doi:10.3390/molecules25122914 · Cited by 28
Pirker, R. (2015) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000260 · Cited by 27
RAS’s Cloak of Invincibility Slips at Last?
Downward, J. (2014) · Cancer Cell · doi:10.1016/j.ccr.2013.12.016 · Cited by 27
EGFR inhibitor and chemotherapy combinations for acquired TKI resistance in EGFR-mutant NSCLC models
Laurila, N., & Koivunen, J. P. (2015) · Medical Oncology · doi:10.1007/s12032-015-0627-6 · Cited by 27
2,4-Diarylamino-pyrimidines as kinase inhibitors co-targeting IGF1R and EGFRL858R/T790M
Chan, S., Han, K., Qu, R., Tong, L., Li, Y., Zhang, Z., Cheng, H., Lu, X., Patterson, A. V., Smaill, J. B., et al. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.07.089 · Cited by 26
Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases
Niggenaber, J., Hardick, J., Lategahn, J., & Rauh, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00964 · Cited by 27
Sakuma, Y., Nishikiori, H., Hirai, S., Yamaguchi, M., Yamada, G., Watanabe, A., Hasegawa, T., Kojima, T., Niki, T., & Takahashi, H. (2016) · Laboratory Investigation · doi:10.1038/labinvest.2015.155 · Cited by 26
Kani, K., Garri, C., Tiemann, K., Malihi, P. D., Punj, V., Nguyen, A. L., Lee, J. S., Hughes, L. D., Alvarez, R. M., Wood, D. M., et al. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0564 · Cited by 26
An, B., Pan, T., Hu, J., Pang, Y., Huang, L., Chan, A. S. C., Li, X., & Yan, J. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111709 · Cited by 26
Presutti, D., Santini, S., Cardinali, B., Papoff, G., Lalli, C., Samperna, S., Fustaino, V., Giannini, G., & Ruberti, G. (2015) · PLoS ONE · doi:10.1371/journal.pone.0143333 · Cited by 25
Dong, L., Lei, D., & Zhang, H. (2017) · Oncotarget · doi:10.18632/oncotarget.19925 · Cited by 25
Novel Cyclic Peptides for Targeting EGFR and EGRvIII Mutation for Drug Delivery
Furman, O., Zaporozhets, A., Tobi, D., Bazylevich, A., Firer, M. A., Patsenker, L. D., Gellerman, G., & Lubin, B. C. R. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071505 · Cited by 27
Cell death in cancer therapy of lung adenocarcinoma
Zagryazhskaya, A., Gyurászová, K., & Zhivotovsky, B. (2015) · The International Journal of Developmental Biology · doi:10.1387/ijdb.150044bz · Cited by 25
Characterization of a new fungal immunomodulatory protein, FIP-dsq2 from Dichomitus squalens
Li, S., Jiang, Z., Sun, L., Liu, X., Huang, Y., Wang, F., & Xin, F. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.02.006 · Cited by 25
Hu, C., Wang, A., Wu, H., Qi, Z., Li, X., Yan, X.-E., Cheng, C., Yu, K., Zou, F., Wang, W., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15443 · Cited by 25
O'Kane, G. M., Barnes, T. A., & Leighl, N. B. (2018) · Current Oncology · doi:10.3747/co.25.3796 · Cited by 25
Chen, Y., Leng, M., Gao, Y., Zhan, D., Choi, J. M., Song, L., Li, K., Xia, X., Zhang, C., Liu, M., et al. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00427 · Cited by 25
Zhao, L., Fan, T., Shi, Z., Ding, C., Zhang, C., Yuan, Z., Sun, Q., Tan, C., Chu, B., & Jiang, Y. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113173 · Cited by 24
Zhang, B., Xu, Z., Liu, Q., Xia, S., Liu, Z., Liao, Z., & Gou, S. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.105420 · Cited by 24
Han, W., & Du, Y. (2017) · Chemistry & Biodiversity · doi:10.1002/cbdv.201600372 · Cited by 24
Chen, L., Fu, W., Feng, C., Qu, R., Tong, L., Zheng, L., Fang, B., Qiu, Y., Hu, J., Cai, Y., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.08.061 · Cited by 24
Patel, H., Pawara, R. H., & Surana, S. J. (2018) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2018.03.026 · Cited by 24
Qin, X., Yang, L., Liu, P., Yang, L., Chen, L., Hu, L., & Jiang, M. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104743 · Cited by 24
Yan, H., Tang, S., Tang, S., Zhang, J., Guo, H., Qin, C., Hu, H., Zhong, C., Li, Y., Zhu, Y., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.949566 · Cited by 24
Treatment of EGFR T790M-Positive Non-Small Cell Lung Cancer
Choo, J. R.-E., Tan, C., & Soo, R. A. (2018) · Targeted Oncology · doi:10.1007/s11523-018-0554-5 · Cited by 24
Overcoming Resistance to AC0010, a Third Generation of EGFR Inhibitor, by Targeting c-MET and BCL-2
Xu, W., Tang, W., Li, T., Zhang, X., & Sun, Y. (2019) · Neoplasia · doi:10.1016/j.neo.2018.11.004 · Cited by 23
Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond.
Karachaliou, N., & Rosell, R. (2014) · PubMed · doi:10.7497/j.issn.2095-3941.2014.03.003 · Cited by 24
Yang, J. C., Reckamp, K. L., Kim, Y., Novello, S., Smit, E. F., Lee, J.-S., Su, W., Akerley, W., Blakely, C. M., Groen, H. J. M., et al. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100114 · Cited by 23
Hu, X., Zhang, S., Ma, Z., Feng, J., Wu, L., Lv, D., Zhou, J., Zhang, X., Liu, L., Yu, Q., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-02865-z · Cited by 26
Self-citationSobh, E. A., Dahab, M. A., Elkaeed, E. B., Alsfouk, A. A., Ibrahim, I. M., Metwaly, A. M., & Eissa, I. H. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2220579 · Cited by 23
Lowder, M. A., Doerner, A. E., & Schepartz, A. (2015) · Journal of the American Chemical Society · doi:10.1021/jacs.5b02326 · Cited by 23
Pan, S., Su, K., Spiessens, B., Kusuma, N., Delahaye, N. F., Gruselle, O., Myo, A., Creus, A. D., Louahed, J., Chang, G.-C., et al. (2016) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.12586 · Cited by 24
Li, Y., Zhang, Y., Zhang, J., Zhan, Z., & Mao, W. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116913 · Cited by 22
Progress of EGFR-TKI and ALK/ROS1 inhibitors in advanced non-small cell lung cancer.
Ge, L., & Shi, R. (2015) · PubMed · Cited by 22
Al-Wahaibi, L. H., Mohammed, A. F., Rahman, F. E.-Z. S. A., Abdelrahman, M. H., Gu, X., Trembleau, L., & Youssif, B. G. M. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2218602 · Cited by 22
Huang, K., Kao, S.-H., Wang, W.-L., Chen, C., Hsiao, T.-H., Salunke, S. B., Chen, J. J. W., Su, K., Yang, S., Hong, T.-M., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201502-0250oc · Cited by 23
Wurz, R. P., Pettus, L. H., Ashton, K., Brown, J., Chen, J. J., Herberich, B., Hong, F., Harrington, E. H., Nguyen, T. T., Jean, D. J. S., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00193 · Cited by 22
Chen, C., Wu, M.-H., Chen, Y., Yen, T.-Y., Lin, Y., Chao, S.-H., Tala, S. D., Tsai, T., Su, T., & Lee, T. (2016) · Neoplasia · doi:10.1016/j.neo.2016.02.005 · Cited by 22
Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer
Klempner, S. J., & Tran, P. N. (2016) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s94337 · Cited by 23
Saad, N., Poudel, A., Basnet, A., & Gajra, A. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s100650 · Cited by 23
Liu, Z., Wang, L., Feng, M., Yi, Y., Zhang, W., Liu, W., Li, L., Liu, Z., Li, Y., & Ma, X. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.01.035 · Cited by 22
Seki, Y., Fujiwara, Y., Kohno, T., Yoshida, K., Goto, Y., Horinouchi, H., Kanda, S., Nokihara, H., Yamamoto, N., Kuwano, K., et al. (2018) · ESMO Open · doi:10.1136/esmoopen-2017-000292 · Cited by 21
Absorption, metabolism, excretion, and safety of [14C]almonertinib in healthy Chinese subjects
Zhou, C., Xie, L., Liu, W. Y., Zhang, L., Zhou, S., Wang, L., Chen, J., Li, H., Zhao, Y., Zhu, B., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-21-1606 · Cited by 21
The marine-derived pachycladin diterpenoids as novel inhibitors of wild-type and mutant EGFR
Mohyeldin, M. M., Akl, M. R., Siddique, A. B., Hassan, H. M., & Sayed, K. A. E. (2016) · Biochemical Pharmacology · doi:10.1016/j.bcp.2016.12.003 · Cited by 21
Zhang, Y., Lv, H., Luo, L., Xu, Y., Pan, Y., Wang, Y., Lin, H., Xiong, J., Guo, P., Zhang, J., et al. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.031 · Cited by 21
Li, X., Shen, W., Jin, X., Ren, P., & Zhang, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-67908-4 · Cited by 21
Li, Y., Chang, Y., Fu, J., Ding, R., Zhang, L., Liang, T., Liu, Y., Liu, Y., & Hu, J. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113845 · Cited by 21
An, B., Liu, J., Fan, Y., Nie, W., Yang, C., Yao, H., Li, W., Zhang, Y., Li, X., & Tian, G. (2022) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2022.105743 · Cited by 21
Dai, L., Qin, F., Xie, Y., Zhang, B., Zhang, Z., Liang, S., Chen, F., Huang, X., & Wang, H. (2023) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2023.106510 · Cited by 20
Drug delivery systems of gefitinib for improved cancer therapy: A review
Nagdiya, D., Kumar, M., Arora, S., Bajaj, T., Kujur, S., Rana, P., Kumar, A., Singh, A., & Singh, C. (2023) · OpenNano · doi:10.1016/j.onano.2023.100183 · Cited by 20
Berz, D., Raymond, V. M., Garst, J. H., & Erlander, M. G. (2015) · Experimental Hematology and Oncology · doi:10.1186/s40164-016-0052-3 · Cited by 20
Wu, S., Zhu, L., Tu, L., Sumei Chen, Huang, H., Zhang, J., Ma, S., & Zhang, S. (2018) · Radiation Research · doi:10.1667/rr14682.1 · Cited by 20
Akher, F. B., Farrokhzadeh, A., & Soliman, M. E. S. (2018) · Chemistry & Biodiversity · doi:10.1002/cbdv.201800518 · Cited by 20
Fu, Q., Huang, Y., Ge, C., Li, Z., Tian, H., Li, Q., Li, H., Li, R., Tao, X., Xue, Y., et al. (2019) · Oncology Reports · doi:10.3892/or.2019.6990 · Cited by 21
Singh, P. K., & Silakari, O. (2017) · Life Sciences · doi:10.1016/j.lfs.2017.08.001 · Cited by 20
EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression
Assche, K. V., Ferdinande, L., Lievens, Y. N., Vandecasteele, K., & Surmont, V. F. M. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00350 · Cited by 19
Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation
Becker, K. D. (2014) · World Journal of Clinical Oncology · doi:10.5306/wjco.v5.i4.560 · Cited by 19
Kovalent‐allosterische Kinase‐Inhibitoren
Weisner, J., Gontla, R., Westhuizen, L. V. D., Oeck, S., Ketzer, J., Janning, P., Richters, A., Mühlenberg, T., Fang, Z., Taher, A., et al. (2015) · Angewandte Chemie · doi:10.1002/ange.201502142 · Cited by 19
Established, emerging and elusive molecular targets in the treatment of lung cancer
Gallant, J., & Lovly, C. M. (2018) · The Journal of Pathology · doi:10.1002/path.5038 · Cited by 22
Li, S., Wu, B., Zheng, X., Wang, C., Zhao, J., Sun, H., Sun, X., Tang, Z., Yuan, H., Chen, L., et al. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104385 · Cited by 19
A grafted peptidomimetic for EGFR heterodimerization inhibition: Implications in NSCLC models
Singh, S. S., Mattheolabakis, G., Gu, X., Withers, S. S., Dahal, A., & Jois, S. D. S. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113312 · Cited by 19
Addressing the Right Targets in Oncology: Challenges and Alternative Approaches
Stock, J. K., Jones, N. P., Hammonds, T. R., Roffey, J., & Dillon, C. (2015) · SLAS DISCOVERY · doi:10.1177/1087057114564349 · Cited by 19
Shades of T790M: Intratumor Heterogeneity in EGFR-Mutant Lung Cancer
Ichihara, E., & Lovly, C. M. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0616 · Cited by 19
Managing Acquired Resistance in EGFR-Mutated Non–Small Cell Lung Cancer
Forde, P. M., & Ettinger, D. S. (2021) · Default Digital Object Group · doi:10.1200/adn.21.200653 · Cited by 19
Updates on the treatment of epidermal growth factor receptor‐mutant non–small cell lung cancer
Kim, J., Park, S., Ku, B. M., & Ahn, M. (2025) · Cancer · doi:10.1002/cncr.35778 · Cited by 20
Ibrahim, M. T., Uzairu, A., Uba, S., & Shallangwa, G. A. (2020) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-020-00074-6 · Cited by 18
Emerging Roles of YES1 in Cancer: The Putative Target in Drug Resistance
Kook, E., Chun, K., & Kim, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25031450 · Cited by 18
Kanthala, S., Liu, Y., Singh, S. S., Sable, R. V., Pallerla, S., & Jois, S. D. S. (2017) · Oncotarget · doi:10.18632/oncotarget.19013 · Cited by 18
Li, Y., Song, Z., Jin, Y., Tang, Z., Kang, J., & Ma, X. (2016) · Molecules · doi:10.3390/molecules21111462 · Cited by 18
Hoshi, H., Hiyama, G., Ishikawa, K., Inageda, K., Fujimoto, J., Wakamatsu, A., Togashi, T., Kawamura, Y., Takahashi, N., Higa, A., et al. (2016) · Oncology Reports · doi:10.3892/or.2016.5227 · Cited by 18
Tanaka, H., Sakagami, H., Kaneko, N., Konagai, S., Yamamoto, H., Matsuya, T., Yuri, M., Yamanaka, Y., Mori, M., Takeuchi, M., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-0976 · Cited by 18
EGFR: New Insights on Its Activation and Mutation in Tumor and Tumor Immunotherapy
Gu, Y., He, H., Qiao, S., Shao, Y., Wang, L., Zhang, Z., Zhang, L., & Zhou, F. (2025) · Advanced Science · doi:10.1002/advs.202505785 · Cited by 19
Isobe, K., Hata, Y., Tochigi, N., Kaburaki, K., Kobayashi, H., Makino, T., Otsuka, H., Ishida, F., Hirota, N., Sano, G., et al. (2015) · PubMed · Cited by 17
Qin, M., Wang, T., Xu, B., Ma, Z., Jiang, N., Xie, H., Gong, P., & Zhao, Y. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.09.031 · Cited by 17
Rho, J. K., Lee, I. Y., Choi, Y. J., Choi, C., Hur, J.-Y., Koh, J. S., Lee, J., Suh, B., Song, H., Salgaonkar, P., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2432 · Cited by 17
Zhang, B., Xu, J., Zhang, X., Gu, P., Wang, H., Wang, S., Qian, J., Qiao, R., Zhang, Y., Yang, W., et al. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.01.006 · Cited by 17
Xia, X., Liu, Y., Liao, Y., Guo, Z., Huang, C., Zhang, F., Jiang, L., Wang, X., Liu, J., & Huang, H. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172409 · Cited by 17
HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
Watanabe, S., Goto, Y., Yasuda, H., Kohno, T., Motoi, N., Ohe, Y., Nishikawa, H., Kobayashi, S. S., Kuwano, K., & Togashi, Y. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13839 · Cited by 17
Zhou, Z., He, J., Yang, F., Pan, Q., Yang, Z., Zheng, P., Xu, S., & Zhu, W. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104848 · Cited by 17
Anticancer activity of D-LAK-120A, an antimicrobial peptide, in non-small cell lung cancer (NSCLC)
Patil, S. M., & Kunda, N. K. (2022) · Biochimie · doi:10.1016/j.biochi.2022.06.011 · Cited by 17
In Vivo Pharmacology Models for Cancer Target Research
Chen, D., An, X., Ouyang, X., Cai, J., Zhou, D., & Li, Q. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9145-7_12 · Cited by 17
Califano, R., Romanidou, O., Mountzios, G., Landi, L. M., Cappuzzo, F., & Blackhall, F. H. (2016) · Drugs · doi:10.1007/s40265-016-0578-z · Cited by 16
Novel Egfr (T790M)-Cmet Dual Inhibitors: Putative Therapeutic Agents for Non-Small-Cell Lung Cancer
Singh, P. K., & Silakari, O. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0234 · Cited by 16
Metadata
- Authors
- Walter, A. O., Sjin, R. T. T., Haringsma, H. J., Ohashi, K., Sun, J., Lee, K., Dubrovskiy, A., Labenski, M., Zhu, Z., Wang, Z., Sheets, M., St Martin, T., Karp, R., van Kalken, D., Chaturvedi, P., Niu, D., Nacht, M., Petter, R. C., Westlin, W., Lin, K., Jaw-Tsai, S., Raponi, M., Van Dyke, T., Etter, J., Weaver, Z., Pao, W., Singh, J., Simmons, A. D., Harding, T. C., & Allen, A.
- Affiliations
- Vanderbilt University (US)
- Authors' Affiliations: 1Clovis Oncology Inc., San Francisco, California; 2Celgene Avilomics Research, Bedford, Massachusetts; 3Division of Hematology-Oncology, Department of Medicine, Vanderbilt University School of Medicine, Nashville, Tennessee; 4Mouse Cancer Genetics Program; and 5Center for Advanced Preclinical Research, Science Applications International Corporation-Frederick, Inc., National Cancer Institute, Frederick, Maryland
- Corresponding author
- Harding, Thomas C.
- ORCID
- Venue
- Cancer Discovery
- Published
- 2013-12-01
- Volume
- 3
- Issue
- 12
- Pages
- 1404-1415
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC4048995
- OpenAlex
- W2146418087
- Cited by
- 620
- References
- 43
- Citations by year
- 2026: 12 · 2025: 17 · 2024: 21 · 2023: 29 · 2022: 32 · 2021: 41 · 2020: 51 · 2019: 44 · 2018: 61 · 2017: 87 · 2016: 92 · 2015: 86 · 2014: 44 · 2013: 3
- FWCI
- 62.72
- Type
- journal article
- Language
- en
- Open access
- green
- kclpure.kcl.ac.uk
- Licence
- other-oa
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (publishedVersion, other-oa)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (HHSN261200800001C)
- National Cancer Institute (P30 CA 68485, R01CA121210, P01CA129243, HHSN261200800001E), U54CA143798, P30CA068485)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- EGFR tyrosine kinase inhibitors, T790M mutation, acquired drug resistance, non-small cell lung cancer, irreversible kinase inhibitors, epithelial-mesenchymal transition, AKT inhibitors, on-target toxicity
- MeSH terms
- Acrylamides, Administration, Oral, Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Drug Screening Assays, Antitumor, Female, Humans, Lung Neoplasms, Mice, Inbred BALB C, Mice, Nude, Mice, Transgenic, Pyrimidines, Drug Resistance, Neoplasm, Xenograft Model Antitumor Assays, Cell Line, Tumor, Protein Kinase Inhibitors, Cell Proliferation, Mutant Proteins, Mice, HEK293 Cells, Epithelial-Mesenchymal Transition, Molecular Targeted Therapy, ErbB Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
